Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Most U.S. kids not meeting sleep, exercise and screen time targets

Just one in 20 U.S. children and teens gets the amount of sleep, exercise and screen time that doctors recommend for optimal health, a new study suggests.

Read More »

Lilly Announces Top-Line Phase 3 Results for Baricitinib in Patients with Moderate to Severe Atopic Dermatitis

Eli Lilly and Company and Incyte Corporation announced that baricitinib met the primary endpoint in BREEZE-AD1 and BREEZE-AD2, two Phase 3 studies evaluating the efficacy and safety of baricitinib monotherapy for the treatment of adult patients with moderate to severe atopic dermatitis.

Read More »

Janssen and MeiraGTx Sign $440 Million Deal to Develop Gene Therapies for Eye Diseases

Janssen Pharmaceutical, a Johnson & Johnson company, inked a worldwide collaboration and license deal with MeiraGTx to develop, manufacture and commercialize a portfolio of drugs for inherited retinal diseases.

Read More »

Israel’s Accelerated Evolution Biotechnologies Claims a Cure for Cancer

Accelerated Evolution Biotechnologies’s claims to have found a cure for cancer are, appropriately, being met with global skepticism.

Read More »

Roche, AC Immune drop Alzheimer’s drug trials

Roche Holding and partner AC Immune called a halt to two late-stage studies of the companies’ crenezumab drug for early Alzheimer’s, the latest in a string of failures to find a treatment for the progressive brain disease.

Read More »

Pfizer and Lilly’s New Type of Pain Drug Meets Endpoints in Osteoarthritis Phase III Trial

Pfizer and Eli Lilly announced that tanezumab hit two out of three co-primary endpoints in one dose and all three with a higher dose in patients with moderate-to-severe osteoarthritis pain in a Phase III trial.

Read More »

Takeda dengue vaccine meets main study goal of trial

Takeda Pharmaceutical’s experimental dengue vaccine appears to be safe and effective at preventing all four types of the mosquito-borne disease, meeting the main goal of a late-stage clinical trial.

Read More »

Alexion’s Ultra-Rare Kidney Disease Drug Passes Phase III With Flying Colors

Boston-based Alexion’s Ultomiris (ravulizumab-cwvz) hit the primary objective in a Phase III study of complement inhibitor-naïve patients with atypical hemolytic uremic syndrome.

Read More »

A Link Between Gum Disease and Alzheimer’s?

Researchers with Cortexyme published research in the journal Science Advances describing the role of Porphyromonas gingivalis, a bacteria that causes gingivitis, to Alzheimer’s disease.

Read More »

Clinical Trial Finds Formula in Merix Pharmaceutical’s RELEEV 1 Day Cold Sore Highly Active Against Herpes

Merix Pharmaceutical Corp. announced the company’s proprietary botanical extract formula VIRACEA was found to be highly active against HSV-1 and HSV-2 in laboratory testing.

Read More »

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

February 2019 Focus: Agenda 2019, Top 10 Pipelines To Watch, Value Of Pharmaceuticals, and more!


Ad Right Bottom